Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors
June 06 2022 - 8:00AM
Business Wire
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage
biopharmaceutical company using an expanded genetic code technology
platform to create Engineered Precision Biologics (EPBs), today
announced the appointment of Janet Loesberg, Pharm. D., to its
Board of Directors.
“I am pleased to welcome Janet as the newest director to Ambrx’s
Board,” said Feng Tian, Ph. D., Chairman of the Board, President,
and CEO of Ambrx. “Janet brings with her more than three decades of
experience in the pharmaceutical industry that spans the US, South
America, Europe and Asia. I am confident that her perspective will
prove valuable in driving Ambrx’s US and global strategy as we
continue to progress our clinical development pipeline.”
Dr. Loesberg has over 30 years of pharmaceutical industry
experience. Dr. Loesberg is currently Senior Vice President Global
Medical Affairs at Blueprint Medicines, a leading precision therapy
company, where she has been since March 2020. From September 2019
to March 2020, Dr. Loesberg was Vice President, Head of Portfolio
and Project Management, Research & Development at Janssen,
Pharmaceutical Companies of Johnson & Johnson where she was
responsible for delivering the extensive pipeline on time and on
budget. Dr. Loesberg also served in several executive roles at
Bristol Myers Squibb from October 2007 to March 2019 including
leading Medical Affairs for the launch of Opdivo in China, Brazil,
Latin America, and many additional countries. She started her
career at Pfizer, Inc. where she also held several US based
leadership roles. Currently, Dr. Loesberg is a board member for All
in Together, a non-profit organization that equips women with tools
to drive meaningful policy change.
Dr. Loesberg holds a Pharm. D. degree from the University of
Michigan, College of Pharmacy.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs), bispecifics, targeted
immuno-oncology therapies, novel cytokines to modulate the immune
system, and long-acting therapeutic peptides for metabolic and
cardiovascular disease. Ambrx is advancing a robust portfolio of
clinical and preclinical programs designed to optimize efficacy,
safety and ease of use, in multiple therapeutic areas, including
its lead product candidate ARX788. In addition, Ambrx has clinical
collaborations with multiple partners, for drug candidates
generated using Ambrx technology. For more information, please
visit www.ambrx.com.
Forward-Looking Statements
This press release includes certain “forward-looking statements”
intended to qualify for the “safe harbor” from liability
established by the Private Securities Litigation Reform Act of
1995, as amended. Forward-looking statements may be identified by
the words “anticipate,” believe,” “estimate,” “expect,” “intend,”
“plan,” “project,” “may,” “will,” “could,” “should,” “seek,”
“potential” and similar expressions, and include, without
limitation, express or implied statements regarding Ambrx’s beliefs
and expectations regarding the advancement and potential benefits
of its product candidates, clinical development and strategic plans
and Dr. Loesberg’s anticipated contributions. Forward-looking
statements are based on Ambrx’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, those risks and
uncertainties associated with: the continuing impact of the
COVID-19 pandemic and other public health-related risks and events
on Ambrx’s business, operations, strategy, goals and anticipated
milestones; Ambrx’s ability to execute on its strategy including
with respect to the timing of its R&D efforts, initiation of
clinical trials and other anticipated milestones; risks associated
with development of novel therapeutics, including potential delays
in clinical trials and regulatory submissions and the fact that
future clinical trial results may not be consistent with
preliminary results or results from prior preclinical studies or
clinical trials; Ambrx’s ability to fund operations as anticipated;
and the additional risks and uncertainties set forth more fully
under the caption “Risk Factors” in Ambrx’s Annual Report on Form
20-F filed with the United States Securities and Exchange
Commission (SEC) on April 26, 2022, and elsewhere in Ambrx’s
filings and reports with the SEC. Forward-looking statements
contained in this press release are made as of this date, and Ambrx
undertakes no duty to publicly update or revise any forward looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220602005175/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 ir@ambrx.com
MEDIA media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Sep 2023 to Sep 2024